Investigating how heme transport affects congenital hydrocephalus development
Defective heme transport in the development of congenital hydrocephalus
This study is looking at how certain genetic and cellular factors might cause congenital hydrocephalus, a condition where fluid builds up in the brain, using mice to help find new ways to treat it and improve outcomes for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-10893936 on NIH RePORTER |
What this research studies
This research focuses on congenital hydrocephalus, a serious neurological condition characterized by the buildup of cerebrospinal fluid in the brain. The study uses a mouse model to explore the role of heme transport in brain development and how disruptions in this process may lead to the condition. By examining the genetic factors and cellular mechanisms involved, the research aims to uncover the underlying causes of congenital hydrocephalus and identify potential therapeutic targets. Patients may benefit from insights gained into the genetic and environmental factors contributing to this condition.
Who could benefit from this research
Good fit: Ideal candidates for participation or benefit from this research include individuals diagnosed with congenital hydrocephalus or those with a family history of the condition.
Not a fit: Patients with acquired hydrocephalus due to trauma or infection may not receive benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new strategies for preventing or treating congenital hydrocephalus.
How similar studies have performed: Other research has shown success in understanding genetic factors in congenital conditions, making this approach promising yet still novel in the context of heme transport.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Arnold, Thomas Darmody — University of California, San Francisco
- Study coordinator: Arnold, Thomas Darmody
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.